1. Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program.

    Neuropathology 35(4):354 (2015) PMID 25619230

    The Brain and Body Donation Program (BBDP) at Banner Sun Health Research Institute (http://www.brainandbodydonationprogram.org) started in 1987 with brain-only donations and currently has banked more than 1600 brains. More than 430 whole-body donations have been received since this service was c...
  2. Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer's disease.

    Expert Opinion on Investigational Drugs 24(3):393 (2015) PMID 25586103

    Reduction in the deposition of amyloid β (Aβ) has been the primary target for Alzheimer's disease (AD) therapeutics recently, but in clinical trials this approach has generally been unsuccessful. A common feature of AD pathology is a complex inflammatory component that could be a target for trea...
  3. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density.

    JAMA Neurology 72(3):287 (2015) PMID 25622185

    In vivo imaging of brain β-amyloid, a hallmark of Alzheimer disease, may assist in the clinical assessment of suspected Alzheimer disease. To determine the sensitivity and specificity of positron emission tomography imaging with flutemetamol injection labeled with radioactive fluorine 18 to dete...
  4. Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer's disease.

    Expert Opinion on Investigational Drugs 24(3):393 (2015) PMID 25586103

    Reduction in the deposition of amyloid β (Aβ) has been the primary target for Alzheimer's disease (AD) therapeutics recently, but in clinical trials this approach has generally been unsuccessful. A common feature of AD pathology is a complex inflammatory component that could be a target for trea...
  5. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density.

    JAMA Neurology 72(3):287 (2015) PMID 25622185

    In vivo imaging of brain β-amyloid, a hallmark of Alzheimer disease, may assist in the clinical assessment of suspected Alzheimer disease. To determine the sensitivity and specificity of positron emission tomography imaging with flutemetamol injection labeled with radioactive fluorine 18 to dete...
  6. Clinical characterization of mild cognitive impairment as a prodrome to dementia with Lewy bodies.

    American Journal of Alzheimer's Disease and Oth... 30(2):173 (2015) PMID 25013117

    Limited information regarding the specificity of mild cognitive impairment (MCI) as it relates to dementia with Lewy bodies (DLB) exists. Here, we summarize the clinical phenotype of MCI in clinically suspect DLB. Ten patients with a primary diagnosis of MCI and secondary diagnoses of DLB were i...
  7. Longitudinal EEG changes correlate with cognitive measure deterioration in Parkinson's disease.

    Journal of Parkinson's Disease 5(1):117 (2015) PMID 25420672

    QEEG could provide physiological biomarkers for changes over time in Parkinson's disease (PD) cognitive decline if they track with longitudinal neuropsychological performance. Our aim was to correlate longitudinal changes in frequency domain quantitative electroencephalography (QEEG) measures wi...
  8. Longitudinal EEG changes correlate with cognitive measure deterioration in Parkinson's disease.

    Journal of Parkinson's Disease 5(1):117 (2015) PMID 25420672

    QEEG could provide physiological biomarkers for changes over time in Parkinson's disease (PD) cognitive decline if they track with longitudinal neuropsychological performance. Our aim was to correlate longitudinal changes in frequency domain quantitative electroencephalography (QEEG) measures wi...
  9. Florbetaben for PET Imaging of Beta-Amyloid Plaques in the Brain.

    NEUROLOGY AND THERAPY 3(2):79 (2014) PMID 26000224

    Alzheimer's disease (AD) is a devastating neurodegenerative disorder affecting the elderly. Current clinical diagnostic tools are often ineffective in accurately diagnosing AD. However, new advances in diagnostic imaging, particularly positron emission tomography (PET) amyloid imaging, have show...
  10. Olfactory dysfunction in incidental Lewy body disease and Parkinson's disease.

    Parkinsonism & Related Disorders 20(11):1260 (2014) PMID 25172126

    Olfactory dysfunction in Parkinson's disease (PD) is well-established and may represent one of the earliest signs of the disease. The objective of this study was to evaluate the relationship of olfactory dysfunction, using the University of Pennsylvania Smell Identification Test (UPSIT), to clin...
  11. Olfactory dysfunction in incidental Lewy body disease and Parkinson's disease.

    Parkinsonism & Related Disorders 20(11):1260 (2014) PMID 25172126

    Olfactory dysfunction in Parkinson's disease (PD) is well-established and may represent one of the earliest signs of the disease. The objective of this study was to evaluate the relationship of olfactory dysfunction, using the University of Pennsylvania Smell Identification Test (UPSIT), to clin...
  12. Olfactory dysfunction in incidental Lewy body disease and Parkinson's disease.

    Parkinsonism & Related Disorders 20(11):1260 (2014) PMID 25172126

    Olfactory dysfunction in Parkinson's disease (PD) is well-established and may represent one of the earliest signs of the disease. The objective of this study was to evaluate the relationship of olfactory dysfunction, using the University of Pennsylvania Smell Identification Test (UPSIT), to clin...
  13. Florbetaben PET imaging to detect amyloid plaques in Alzheimer disease: Phase 3 study

    Alzheimer's & Dementia (2014)

    Background Evaluation of brain β-amyloid by PET imaging can assist in the diagnosis of Alzheimer disease (AD) and other dementias.
  14. Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations.

    Parkinsonism & Related Disorders 20(9):1009 (2014) PMID 25027359 PMCID PMC4143433

    Previous research has linked complex or formed visual hallucinations (VH) to Lewy-type alpha-synucleinopathy (LTS) in neocortical and limbic areas. As Alzheimer's disease pathology often co-occurs with LTS, we questioned whether this pathology - amyloid plaques and neurofibrillary tangles - migh...
  15. Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimer's disease.

    Neurobiology of Aging 35(9):1961 (2014) PMID 24786631 PMCID PMC4067010

    Mild cognitive impairment (MCI) represents a cognitive state intermediate between normal aging and early Alzheimer's disease (AD). To investigate if the molecular signature of MCI parallels the clinical picture, we use microarrays to extensively profile gene expression in 4 cortical brain region...
  16. Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimer's disease.

    Neurobiology of Aging 35(9):1961 (2014) PMID 24786631 PMCID PMC4067010

    Mild cognitive impairment (MCI) represents a cognitive state intermediate between normal aging and early Alzheimer's disease (AD). To investigate if the molecular signature of MCI parallels the clinical picture, we use microarrays to extensively profile gene expression in 4 cortical brain region...
  17. Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study.

    Neurology 83(5):406 (2014) PMID 24975862 PMCID PMC4132570

    Determine diagnostic accuracy of a clinical diagnosis of Parkinson disease (PD) using neuropathologic diagnosis as the gold standard. Data from the Arizona Study of Aging and Neurodegenerative Disorders were used to determine the predictive value of a clinical PD diagnosis, using 2 clinical diag...
  18. Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study.

    Neurology 83(5):406 (2014) PMID 24975862 PMCID PMC4132570

    Determine diagnostic accuracy of a clinical diagnosis of Parkinson disease (PD) using neuropathologic diagnosis as the gold standard. Data from the Arizona Study of Aging and Neurodegenerative Disorders were used to determine the predictive value of a clinical PD diagnosis, using 2 clinical diag...
  19. Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study.

    Neurology 83(5):406 (2014) PMID 24975862 PMCID PMC4132570

    Determine diagnostic accuracy of a clinical diagnosis of Parkinson disease (PD) using neuropathologic diagnosis as the gold standard. Data from the Arizona Study of Aging and Neurodegenerative Disorders were used to determine the predictive value of a clinical PD diagnosis, using 2 clinical diag...
  20. Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinson's disease subjects.

    Neuroscience Letters 571:34 (2014) PMID 24785101

    Visual symptoms are relatively common in Parkinson's disease (PD) and optical coherence tomography has indicated possible retinal thinning. Accumulation of aggregated α-synuclein is thought to be a central pathogenic event in the PD brain but there have not as yet been reports of retinal synucle...